Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis by Fluge, Ø et al.
Expression of EZH2 and Ki-67 in colorectal cancer and
associations with treatment response and prognosis
Ø Fluge
1, K Gravdal
2, E Carlsen
3, B Vonen
4, K Kjellevold
5, S Refsum
6, R Lilleng
7, TJ Eide
8, TB Halvorsen
9,
KM Tveit
10, AP Otte
11, LA Akslen
12,2 and O Dahl*,13,1, for the Norwegian Gastrointestinal Cancer Group
1Department of Oncology, Haukeland University Hospital, Bergen, Norway;
2Department of Pathology, Haukeland University Hospital, Bergen, Norway;
3Department of Surgery, Ulleva ˚l University Hospital, Oslo, Norway;
4Department of Surgery, University of Northern Norway, Tromsø, Norway;
5Department of Pathology, Stavanger University Hospital, Stavanger, Norway;
6Laboratory for Pathology AS, Oslo, Norway;
7Department of Pathology,
Buskerud Central Hospital, Drammen, Norway;
8Department of Pathology, The National Hospital, Oslo, Norway;
9Department of Pathology, St Olav’s
Hospital, Trondheim, Norway;
10Department of Oncology, Ulleva ˚l University Hospital, Oslo, Norway;
11Department of Biochemistry, Swammerdam
Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands;
12The Gade Institute, Department of Pathology, University of Bergen,
Bergen, Norway;
13Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway
BACKGROUND: Enhancer of zeste homologue 2 (EZH2) is a member of the Polycomb group of genes that is involved in epigenetic
silencing and cell cycle regulation.
METHODS: We studied EZH2 expression in 409 patients with colorectal cancer stages II and III. The patients were included in a
randomised study, and treated with surgery alone or surgery followed by adjuvant chemotherapy.
RESULTS: EZH2 expression was significantly related to increased tumour cell proliferation, as assessed by Ki-67 expression. In colon
cancer, strong EZH2 expression (P¼0.041) and high proliferation (X40%; P¼0.001) were both associated with better relapse-free
survival (RFS). In contrast, no such associations were found among rectal cancers. High Ki-67 staining was associated with improved
RFS in colon cancer patients who received adjuvant chemotherapy (P¼0.001), but not among those who were treated by surgery
alone (P¼0.087). In colon cancers stage III, a significant association between RFS and randomisation group was found in patients with
high proliferation (P¼0.046), but not in patients with low proliferation (P¼0.26). Multivariate analyses of colon cancers showed that
stage III (hazard ratio (HR) 4.00) and high histological grade (HR 1.80) were independent predictors of reduced RFS, whereas high
proliferation indicated improved RFS (HR 0.55).
CONCLUSION:Strong EZH2 expression and high proliferation are associated features and both indicate improved RFS in colon cancer,
but not so in rectal cancer.
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Colorectal cancer is among the most common malignancies, and is
one of the leading causes of cancer deaths in the western world.
Although adequate surgery is the main treatment, adjuvant
chemotherapy has since 1990 been considered standard to patients
with lymph node metastases (Wolmark et al, 1988; Laurie et al,
1989; Moertel et al, 1990; Andre et al, 2004; de Gramont et al,
2007). The search for molecular markers with prognostic or
especially predictive effect is important to select patients for
proper therapy, and to avoid unnecessary treatment with toxic side
effects.
Enhancer of zeste homologue 2 (EZH2) is a member of the
Polycomb group of genes (Chen et al, 1996), encoding a
transcriptional repressor as part of the histone methyltransferase
complex (van der Vlag and Otte, 1999), with important functions
in epigenetic silencing and cell cycle regulation. EZH2 is an E2F-
regulated gene (Bracken et al, 2003), and activated p53 may
downregulate EZH2 transcription through repression of the
promoter (Tang et al, 2004). Overexpression of EZH2 protein
has been shown in several carcinomas, and has been associated
with increased tumour cell proliferation and worse outcome in
breast cancer (Collett et al, 2006), melanomas, endometrial
carcinomas (Bachmann et al, 2006), and also in hormone-
refractory prostate cancer (Bryant et al, 2007).
In this study we analysed the expression of EZH2 protein and
the proliferation marker Ki-67, using tissue microarrays and
immunohistochemistry, in 409 patients with colorectal cancer in
stages II and III, randomised to either surgery alone or to surgery
and adjuvant chemotherapy with 5-fluorouracil (5-FU) and
levamisol (FLev).
MATERIALS AND METHODS
From December 1992 to October 1996, a total of 425 patients with
colorectal cancer were included in a prospective randomised
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sclinical study. The inclusion criteria and patient characteristics
have been presented earlier (Dahl et al, 2009). In brief, before
inclusion the patients should have a histopathologically confirmed
radical surgical resection of the primary tumour and regional
lymph nodes. The patients should have no evidence of distant
metastases evaluated by chest X-ray, ultrasound or computed
tomography of the abdomen, and blood tests including carci-
noembryonal antigen (CEA). The patients were between 18 and 75
years of age, and had no concurrent diseases precluding the
administration of systemic chemotherapy. Patients with primary
tumour localisation in the colon or the rectum, and histopatho-
logical tumour–node–metastasis (TNM) stage II (penetration of
muscularis propria) or TNM stage III (with lymph node
metastases) were eligible for inclusion. The patients were randomly
allocated to the treatment groups, and were treated according to
this schedule. None of the patients with rectal cancer received
preoperative radiotherapy. The inclusion criteria were adequately
met for 412 patients, and these were included in the statistical
analyses. All data were collected at the Regional Research Office
and then centralised to the office in Bergen, Norway, where all the
data handling took place. All patients had to give their written
informed consent before randomisation. The study was approved
by the regional ethics committee, The Norwegian Medicines
Control Authority, and the Data Inspectorate.
Chemotherapy and follow-up
A loading course of 5-FU was started within 42 days from the date
of surgery, giving 450mgm
 2 intravenously (i.v.) daily for 5 days
and levamisol 50mg 3 for the first 3 days. After 3 weeks,
maintenance therapy was started with weekly i.v. 5-FU
450mgm
 2, combined with levamisol 50mg 3 for 3 days every
second week, for a total maintenance therapy period of 48 weeks.
The patients were thereafter observed regularly every 6 months
with clinical examination including chest X-ray, ultrasound of the
abdomen, and relevant endoscopical examination, including
coloscopy every 3 years. The follow-up time was scheduled for 5
years. For 272 patients without relapse, the median follow-up time
was 7 years.
Tissue microarray and immunohistochemistry
The paraffin-embedded and formalin-fixed tissue specimens were
available from 409 out of 412 eligible patients for tissue
microarrays (TMA). Cylinders, 1mm in diameter, were punched
from the representative areas of tumour cell infiltration in the
primary tumours, from macroscopically normal colon or rectal
mucosa, and from lymph nodes with synchronous metastases,
which were mounted in recipient paraffin blocks using a standard
precision instrument (Manual Tissue Arrayer MTA-1, Beecher
Instruments, Inc., Sun Prairia, WI, USA). A total of about 1400
cylinders were mounted, varying from one to three representative
samples from each tumour, and one from normal colon or rectal
mucosa, and from lymph node metastases.
EZH2 staining was performed on a DAKO autostainer using the
EnVision method, and the TMA slides were incubated for 1h using
the monoclonal antibody (clone M18) specific for EZH2, as
described (Collett et al, 2006). Ki-67 immunostaining was
performed on formalin-fixed and paraffin- embedded tissue using
5mm sections. After microwave antigen retrieval (boiling for
15min at 400W) in Tris-ethylenediaminetetraacetic acid buffer
(pH 9.0), the slides were incubated for 30min at room temperature
with the monoclonal mouse anti-human Ki-67 antibody (clone
MIB-1) Cat. no. M 7240 (Dako, Copenhagen) diluted 1:250, and
stained with horseradish peroxidase (HRP) EnVision (Dako) for
30min at room temperature. HRP was localised using the
diaminobenzidine tetrachloride peroxidase reaction and the
sections were counterstained with Mayer’s haematoxylin.
For EZH2, tumour cell nuclear staining intensity (score 0–3),
and the fraction of positive tumour cells (score 0–3), were
identified by a skilled pathologist blinded from the follow-up data.
The EZH2 fraction of positive tumour cells was categorised as
follows: 0, 0%; 1, o10%; 2, 10–50%; and 3, 450%. The EZH2
staining intensity was recorded as: 0, no staining; 1, weak; 2,
moderate; and 3, strong staining. A staining index (SI) was
generated from the product (0–9), and then categorised in either
three (SI 0–1, 2–4, 6–9) or two (SI 0–3, 4–9) groups. For Ki-67
immunohistochemistry, the percentage of positive tumour cells
was assessed in several representative visual fields of each tumour.
A cutoff was then chosen at the median value, dividing the samples
in low (o40% positive tumour cells) or high nuclear Ki-67
expression (X40%). This cutoff is also supported by another study
(Salminen et al, 2005).
Statistics
The survival data were calculated according to the product-limit
procedure (Kaplan–Meier method), and P-values were based on
Table 1 Univariate associations of variables with relapse-free survival
within colon cancer, TNM stages II and III
No. Relapse
5-year relapse-
free survival
(%)
s.e.
(%) P-value
Age NS
p60 years 113 33 71 4
460 years 177 52 71 4
Sex NS
Women 152 48 69 4
Men 138 37 73 4
TNM stage o0.001
Stage II 185 31 83 3
Stage III 105 54 48 5
Randomisation group
a NS
Adjuvant therapy 149 41 73 4
Surgery alone 141 44 68 4
Randomisation group
b 0.012
Adjuvant therapy 54 23 58 7
Surgery alone 51 31 37 7
Ki-67 0.001
p40% 134 54 60 4
440% 129 26 80 4
EZH2 0.041
Index 0–3 200 68 66 3
Index 4–9 41 7 82 6
Histological type NS
Adenocarcinoma 250 74 70 3
Variant
c 32 6 80 7
Histological grade 0.025
High/moderate 228 62 73 3
Poor differentiation 56 22 59 7
Tumour localisation NS
Proximal colon 161 41 74 4
Distal colon 129 44 67 4
Abbreviations: EZH2¼enhancer of zeste homologue 2; NS¼not significant;
TNM¼tumor–node–metastasis.
aIncluding both TNM stages II and III.
bIncluding
TNM stage III.
cVariant histology includes mucinous and signet-ring carcinomas.
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sthe log-rank test, with a P-value of o0.05 considered statistically
significant in two-tailed tests. Kaplan–Meier analyses for survival
were performed for relapse-free survival (RFS) and for cancer-
specific survival (CSS), including death for colorectal cancer and
death from treatment-related complications as outcome events.
The associations between EZH2 protein expression and
different categorical clinicopathological variables were analysed by
Pearson’s chi-square test. Cox’ regression analysis was performed
to assess independent prognostic factors for RFS in colon cancer,
Figure 1 Strong (top) and weak (bottom) nuclear EZH2 staining in
tumour cells.
Table 2 The proportion of cases (%) for different clinical and histological variables, according to EZH2 protein expression (A) and Ki-67 protein
expression (B)
(A)
EZH2 protein expression
Variable Index 0–1, n¼124 Index 2–4, n¼87 Index 6–9, n¼29 P-value *
Sex (n¼240, female, %) 55.6 54.0 44.8 NS
Age (n¼240, mean, years) 62.2 61.6 63.2 NS
Tumour localisation (n¼240, proximal colon, %) 52.4 58.6 55.2 NS
Tumour stage (n¼240, T3 and T4, %) 93.6 97.4 93.1 NS
Histological type
a (n¼232, adenocarcinoma, %) 93.4 81.9 92.9 0.028
Histological grade (n¼235, poorly differentiated, %) 18.7 19.0 17.9 NS
TNM stage (n¼240, stage III, %) 41.4 34.5 27.6 0.14**
Ki-67 (n¼230, 440% tumour cells positive, %) 34.7 56.6 96.6 o0.001
Randomisation group (n¼240, adjuvant chemotherapy, %) 47.6 55.2 51.7 NS
(B)
Ki-67 protein expression
Variable o40%, n¼134 X40 %, n¼129 P-value *
Sex (n¼263, female, %) 52.2 54.3 NS
Age (n¼263, mean, years) 61.6 61.6 NS
Tumour localisation (n¼263, proximal colon, %) 56.0 56.6 NS
Tumour stage (n¼263, T3 and T4, %) 93.3 96.9 NS
Histological type
a (n¼256, adenocarcinoma, %) 91.6 87.2 NS
Histological grade (n¼257, poorly differentiated, %) 21.1 16.9 NS
TNM stage (n¼263, stage III, %) 42.5 31.8 0.07
EZH2 protein expression (¼230, index 4–9, %) 6.1 29.1 o0.0001
Randomisation group (n¼263, adjuvant chemotherapy, %) 51.5 51.9 NS
Abbreviations: EZH2¼enhancer of zeste homologue 2; NS¼not significant; TNM¼tumour–node–metastasis. Analyses include patients with colon cancer in TNM stages II
and III. *P-values from chi-square statistics. NS: P40.10. **P for trend.
aOther histological types include mucinous adenocarcinoma and signet-ring cell carcinoma.
EZH2 index 0–1
n=170
EZH2 index 2–4
n=120
EZH2 index 6–9
n=39
K
i
-
6
7
 
p
e
r
c
e
n
t
 
p
o
s
i
t
i
v
e
 
t
u
m
o
u
r
 
c
e
l
l
s
< 10
11–20
21–30
31–40
41–60
> 60
Figure 2 Association between EZH2 staining index and the percentage
of Ki-67-positive tumour cells.
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sincluding the variables stage (II vs III), Ki-67 staining (o40% vs
X40% positive tumour cell nuclei), tumour differentiation (high
or moderate differentiation vs poor differentiation), randomisation
group (adjuvant chemotherapy vs surgery alone), and tumour
localisation (proximal vs distal colon), and the variables were
included in a single step. The data handling was performed by the
SPSS software package (version 16.0).
RESULTS
Among the 412 patients included, 290 had colon cancer (185 in
stage II and 105 in stage III), and 122 had rectal cancer (62 in stage
II and 60 in stage III). In all, 206 patients were randomised to each
group (with or without adjuvant chemotherapy), 215 were men
and 197 women, and the mean age at randomisation was 61.3 years
(range 28.4–75.1). The details of the patient characteristics have
been described earlier (Dahl et al, 2009).
For all patients included, that is, both colon and rectal cancer
(stages II and III), Kaplan–Meier analyses showed significantly
better RFS for tumour localisation in colon vs rectum (5-year RFS
71 vs 55%, P¼0.003), for tumour grade (5-year RFS 67% for high
or moderate grade vs 55% for poorly differentiated, P¼0.022), for
stage (5-year RFS 82% for stage II vs 42% for stage III, Po0.001),
for EZH2 expression (5-year RFS 79% for index 4–9 vs 63% for
index 0–3, P¼0.038), and for Ki-67 expression (5-year RFS 73%
for X40% vs 59% for o40%, P¼0.003). In the complete patient
series, there were no significant associations between RFS and the
randomisation group (5-year RFS 69% for adjuvant treatment vs
63% for surgery alone, P¼0.24), or between RFS and age or sex.
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Figure 3 Kaplan–Meier survival analyses for high EZH2 staining index (4–9) vs low EZH2 index (0–3) in colon cancer stages II and III (A), rectal cancer
stages II and III (B), colon cancer stage II (C), colon cancer stage III (D), in colon cancer patients of stages II and III receiving adjuvant chemotherapy (E), and
in colon cancer patients of stages II and III with no adjuvant therapy (F). P-values are from log-rank tests.
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sWithin patients with colon cancer (stages II and III), the
univariate associations between clinicopathological variables and
RFS are shown in Table 1. As expected, the presence of lymph node
metastases (stage III) was associated with a reduced 5-year RFS
rate (Po0.001). Adjuvant therapy was significantly associated with
better RFS in colon cancer stage III (P¼0.012), but not when
analysing colon cancer stages II and III together (P¼0.35).
EZH2 protein expression is shown in Figure 1. The associations
of EZH2 protein expression and the clinicopathological variables,
for patients with colon cancer stages II and III, are shown in
Table 2. There was a significant association between a high EZH2
index and increased tumour cell proliferation, as assessed by
Ki-67 expression (Po0.001; Figure 2). There were no significant
associations between EZH2 index and the sex, age, tumour
localisation (proximal vs distal colon), histological grade, rando-
misation group, or tumour stage. The proportion of patients with
stage III was 41.4% in those with a low EZH2 index (0–1) as
compared with 34.5% in those with index 2–4, and 27.6%
in patients with a high index, but this was not significant
(P for trend 0.14).
Figure 3 shows Kaplan–Meier curves for the effect of EZH2
expression (high index 4–9, vs low index 0–3). In colon cancer
stages II and III, a high EZH2 index was significantly associated
with a better RFS (Figure 3, panel A, P¼0.041 by the log-rank
test), and with a trend for better CSS (P¼0.069). In rectal cancer
stages II and III, no differences in RFS or CSS were detected for
high vs low EZH2 index (Figure 3, panel B, P¼0.46).
A corresponding subgroup analysis within colon cancer stage III
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Figure 4 Kaplan–Meier survival analyses for high Ki-67 expression (X40% positive tumour cells) vs low Ki-67 expression (o40% tumour cells) in colon
cancer stages II and III (A), rectal cancer stages II and III (B), colon cancer stages II and III receiving adjuvant therapy (C), colon cancer stages II and III
with no adjuvant therapy (D), colon cancer stage III receiving adjuvant therapy (E), and colon cancer stage III with no adjuvant therapy (F). P-values are from
log-rank tests.
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spatients showed a trend for improved RFS with high EZH2 index
(P¼0.097), whereas a similar analysis for CSS was not significant
(P¼0.14; Figure 3, panels C and D). In colon cancer stages II and
III, there were trends for better RFS (P¼0.077) and CSS
(P¼0.085) with a high EZH2 index in patients receiving adjuvant
chemotherapy (Figure 3, panel E), but not in patients with no
adjuvant therapy (Figure 3, panel F).
Ki-67 expression in 440% of the tumour cells was significantly
associated with improved RFS (P¼0.001) and CSS (P¼0.001) in
patients with colon cancer stages II and III (Figure 4, panel A), but
not in rectal cancer (Figure 4, panel B, P¼0.98 for RFS, P¼0.96
for CSS). In Figure 4, panels C and D, subgroup analyses in
patients receiving adjuvant treatment and those randomised to
surgery alone (stages II and III) are shown. A high Ki-67
expression was significantly associated with an improved RFS
(P¼0.001, Figure 4, panel C) and improved CSS (P¼0.003) in the
adjuvant group, but only with a trend for better RFS (P¼0.087)
and with no significant affect on CSS (P¼0.11) in the group
treated with surgery alone (Figure 4, panel D). Correspondingly, in
patients with colon cancer stage III, Kaplan–Meier curves showed
significant associations between a high Ki-67 (X40%) and better
RFS (P¼0.007) and CSS (P¼0.017) in the group that was given
adjuvant treatment, but not in the group without adjuvant
chemotherapy. In the adjuvant group, 5-year RFS was 77% in
those with a high Ki-67, and 36% in those with low Ki-67
(P¼0.007; Figure 4, panel E). The corresponding figures for 5-year
CSS were 81% in patients with a high Ki-67, and 51% in those with
low Ki-67 (P¼0.017). In the group without adjuvant therapy,
5-year RFS was 50% in those with a high Ki-67 vs 29% in those
with a low Ki-67 (P¼0.39; Figure 4, panel F), whereas the figures
for CSS were 55 and 44% (P¼0.38).
The results of Cox’ multivariate analyses, including 256 out of
284 patients with colon cancer stages II and III, are shown in
Table 3. The significant independent predictors for reduced RFS
were stage III (hazard ratio (HR) 4.00, 95% confidence interval
(CI) 2.50–6.39), high histological tumour grade (HR 1.80, 95% CI
1.09–2.98), whereas a high Ki-67 expression (X40%) was
independently associated with an improved RFS (HR 0.55, 95%
CI 0.34–0.89). Randomisation group (P¼0.31), and tumour
localisation (proximal vs distal colon, P¼0.27) were not indepen-
dently associated with RFS in colon cancer stages II and III.
Finally, in Figure 5 are presented the results of Kaplan–Meier
analyses in 98 patients with colon cancer stage III, with separate
panels for those with a high Ki-67 expression (X40%, n¼41) and
those with a low Ki-67 expression (o40%, n¼57), showing the
effect of randomisation group on RFS. In patients with a low Ki-67
protein expression in the primary tumours, no association was
found between randomisation group and RFS (Figure 5, panel A,
P¼0.26). In contrast, in the group of patients with colon cancer
stage III and a high Ki-67 expression, 5-year RFS in those receiving
adjuvant chemotherapy was 77% (s.e. 0.09) as compared with 50%
(s.e. 0.12) in those treated with surgery without adjuvant
chemotherapy (P¼0.046). The corresponding figures for 5-year
CSS were 81% in patients receiving adjuvant chemotherapy
(s.e. 0.09) compared with 56% (s.e. 0.12) in those with surgery
alone (P¼0.070).
DISCUSSION
In this study, patients with colorectal cancer stages II and III were
randomised to either surgery alone, or the addition of 1 year of
adjuvant therapy with FLev. This chemotherapy regimen is no
longer a standard practice for adjuvant treatment of colon cancer
stage III, because of the introduction of more effective regimens,
Table 3 Independent predictors for relapse-free survival in 256 patients
with colon cancer TNM stages II and III, according to Cox regression model
Variable Hazard ratio (95% CI) P-value
TNM stage o0.0001
Stage II 1
Stage III 4.00 (2.50–6.39)
Ki-67 staining 0.014
o40% 1
X40% 0.55 (0.34–0.89)
Tumour grade 0.022
High or moderate differentiation 1
Poor differentiation 1.80 (1.09–2.98)
Randomisation group 0.31
No adjuvant therapy 1
Adjuvant chemotherapy 0.80 (0.51–1.24)
Tumour localisation 0.27
Proximal colon 1
Distal colon 1.28 (0.82–1.99)
Abbreviations: CI¼confidence interval; TNM¼tumor–node–metastasis. Cox
analysis (enter) was based on 256 out of 284 patients with colon cancer TNM
stages II and III, and 28 cases had missing data for one variable.
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Figure 5 Kaplan–Meier survival analyses for colon cancer stage III patients receiving adjuvant therapy vs colon cancer stage III patients with no adjuvant
therapy. Separate panels for patients with low Ki-67 expression (o40% positive tumour cells) (A), and for patients with high Ki-67 expression (X40%
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sincluding the cytotoxic drug oxaliplatin (Andre et al, 2004).
However, a strength of this study is that adjuvant FLV
chemotherapy was compared with surgery alone, which would be
considered unethical nowadays.
We studied the affect of EZH2 protein expression and the
proliferation marker Ki-67 on survival. EZH2 expression was
significantly correlated with tumour cell proliferation as assessed
by the percentage of Ki-67-positive cells, but not to other
clinicopathological variables. EZH2 is a cell cycle regulator
necessary for G2-M transition and is an E2F-regulated gene
(Bracken et al, 2003). The association between proliferation and
EZH2 expression has been shown in other malignancies such as
breast cancer and melanomas (Bachmann et al, 2006; Collett et al,
2006). In these malignancies, EZH2 expression in tumour cells was
linked to an aggressive clinical behaviour and worse prognosis. In
addition, in prostate cancer cells, EZH2 was found to promote
invasiveness and proliferation (Bryant et al, 2007). In our study, a
high EZH2 index was associated with a better RFS in colon cancer
stages II and III, but not in rectal cancer. Subgroup analyses
showed that this benefit was primarily in patients with colon
cancer stage III, but this did not reach statistical significance.
Unexpectedly, and in line with our EZH2 data, Ki-67 protein
expression in 440% of the tumour cells was also associated with a
better RFS in colon cancer stages II and III. This association was
not observed in rectal cancer patients. Another study of rectal
cancers has shown significant association between high Ki-67
(440%) and improved survival (Salminen et al, 2005). The
prognostic value of Ki-67 was significant in colon cancer patients
with stage III who were receiving adjuvant chemotherapy.
However, in colon cancer patients treated with surgery without
adjuvant chemotherapy, only a trend for improved RFS was found
for those with a high Ki-67 expression. Thus, a high tumour cell
proliferation rate, as assessed by Ki-67 immunohistochemistry, is
not an adverse prognostic marker in colorectal cancer stages II and
III patients receiving adjuvant treatment. In fact, for colon cancer
stages II and III, a high Ki-67 expression is associated with an
improved RFS.
Among the colon cancer patients, the percentage of stage III
patients was higher in those with a low Ki-67 expression than in
those with a high Ki-67 (42.5% vs 31.8%), but this difference was
not significant (P¼0.07). In addition, the multivariate survival
analyses, performed on colon cancer patients stages II and III,
showed that a high Ki-67 immunostaining was an independent
prognostic variable for an improved RFS and TNM stage and
histological tumour grade.
Interestingly, the survival analyses performed separately for
colon cancer stage III patients, and stratified according to Ki-67
expression, showed a significant association between RFS and the
randomisation group only for patients with a high Ki-67
expression. Thus, in colon cancer stage III patients, a high Ki-67
expression (440%) seems to be a predictive marker for the effect
of 12-month adjuvant chemotherapy with FLV. EZH2 protein
expression was not a significant predictive marker in this aspect.
The prognostic value of Ki-67 in different malignancies has been
reviewed (Brown and Gatter, 2002). The most consistent data for
an adverse prognostic value of a high Ki-67 have been reported for
breast cancer (Baak et al, 2009), lung cancer, and sarcomas. For
cervical cancer and prostate cancer, the reports on the associations
between clinical outcome and Ki-67 expression have been varying
(Brown and Gatter, 2002).
In colorectal cancer, data have, to some extent, been contra-
dictory. Several studies have reported no prognostic value of Ki-67
expression. One study reported an association between a low
tumour cell proliferation rate at the invasive margin and poor
prognosis in colorectal cancer TNM stage II (Palmqvist et al,
1999), whereas others reported an adverse prognostic value of a
high Ki-67 after curative resection for colorectal cancer (Kimura
et al, 2000). In accordance with our data, a study of prognostic
markers in colon cancer stage II and III, treated with surgery with
or without adjuvant 5-FU and leucovorin (calcium folinate)
therapy, showed an improved outcome in patients with a high
percentage of Ki-67-positive tumour cells (Allegra et al, 2003). As a
possible explanation, more rapidly proliferating tumour cells may
be more vulnerable to chemotherapy-induced tumour cell death.
We conclude that increased EZH2 protein expression and Ki-67
expression in 440% of the tumour cells are both associated with
an improved RFS in colon cancer stages II and III, but not so in
rectal cancer. In addition, in colon cancer stage III, a high
Ki-67 immunostaining in 440% of the tumour cells seems to
be a predictive marker to the effect of adjuvant chemotherapy
using FLV.
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